Drug intelligence / Profile preview

Icy Hot

Development stage: Preclinical
Lead developer: Opella Healthcare Group
Modality: Small Molecules
Administration: Topical, Transdermal

Overview

Icy Hot is a topical analgesic used for the relief of minor musculoskeletal pain. It contains active ingredients such as **menthol** and **methyl salicylate**. Menthol provides a cooling sensation by activating cold-sensing receptors, while methyl salicylate acts as a counterirritant, creating minor inflammation to distract from pain. Additionally, methyl salicylate has been found to have cardioprotective effects by activating TRPA1 receptors, which trigger downstream signaling pathways for cardiac protection[1][2][5].

Brand names: Icy Hot

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on Icy Hot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Icy Hot.

Explore the full profile